

**Factors affecting the immunogenicity
and protective efficacy
of routine childhood immunisations**



Thesis submitted in requirement for the degree
of Doctor of Philosophy

The University of Adelaide
FACULTY OF HEALTH SCIENCES

Department of Paediatrics

Christina Ann Boros, M.B.B.S., F.R.A.C.P.

Date of Submission: December 2001

Table of Contents

INDEX OF TABLES	11
INDEX OF FIGURES	13
ABSTRACT	16
PUBLICATIONS ARISING FROM THIS THESIS	21
DECLARATION	22
ACKNOWLEDGEMENTS	23
ABBREVIATIONS AND STANDARD UNITS	25
CHAPTER 1. LITERATURE REVIEW	27
1.1 Pertussis infection: the scope of the problem	27
1.1.1 The spectrum of clinical features of pertussis with age	27
1.2 Microbiology of <i>Bordetella pertussis</i>	29
1.2.1 <i>B. pertussis</i> virulence factors: control of expression	29
1.2.2 <i>B. pertussis</i> virulence factors: description	31
1.2.2.1 Pertussis Toxin (PT)	31
1.2.2.2 Filamentous haemagglutinin (FHA)	31
1.2.2.3 Pertactin (PRN)	32
1.2.2.5 Fimbriae	32
1.2.2.6 Adenylate cyclase toxin/haemolysin	32
1.2.2.7 Tracheal cytotoxin	33
1.2.2.8 Dermonecrotic toxin	33
1.2.2.9 Lipopolysaccharide	34
1.3 Pertussis vaccines: historical overview	34
1.3.1 Whole cell vaccines	34
1.3.2 Acellular vaccines	36
1.4 History of pertussis and pertussis vaccines in Australia	37
1.4.1 Compulsory notification of disease	38
1.4.2 Persistent disease reservoir	39
1.4.3 Vaccine coverage rates	39
1.4.4 Changes in pertussis serotypes and virulence factors	41
1.4.4.2 Virulence factors	42
1.5 Epidemiology of other vaccine preventable diseases	42
1.5.1 Diphtheria	42
1.5.2 Tetanus	43
1.5.3 <i>Haemophilus influenzae</i> type b infection (Hib)	44

1.6	Vaccine storage	45
1.6.1	Vaccine cold chain	45
1.6.1.1	Vaccine temperature monitoring devices	46
1.6.1.1.1	Vaccine vial monitors	46
1.6.1.1.2	Freezewatches	46
1.6.1.1.3	Time Temperature integrators	47
1.6.1.1.4	Electronic minimum-maximum thermometers	47
1.6.1.1.5	Electronic monitors	48
1.6.2	Methods of determining the effect of adverse temperature storage on triple antigen (DTP) vaccines	48
1.6.2.1	Effects on the adjuvant	48
1.6.2.2	Effects on vaccine antigens	49
1.6.2.2.1	Methods of measuring the efficacy of pertussis vaccines	49
1.6.2.3	Review of previous studies investigating the effect of adverse storage on the efficacy of DTPw vaccines	52
1.6.2.3.1	The pertussis component of DTPw preparations	52
1.6.2.3.1.1	Higher temperature storage	52
1.6.2.3.1.2	Storage at lower temperatures	53
1.6.2.3.2	Diphtheria and tetanus toxoids	53
1.6.2.3.2.1	High temperature storage	53
1.6.2.3.2.2	Storage at lower temperatures	54
1.7	Mechanisms of immunity against pertussis infection	55
1.7.1	Humoral immunity	55
1.7.2	Cell-mediated immunity	57
1.7.2.1	Murine studies	57
1.7.2.2	Human studies	59
1.7.2.2.1	Studies in human adults	60
1.8	Neonatal immune function	61
1.8.1	Neonatal Humoral Immunity	61
1.8.2	Neonatal cell-mediated immunity	62
1.8.2.1	Implications for responses to immunisation	63
1.8.2.2	Implications for the immunisation of premature neonates	65
1.9	Rationale for studies presented in this thesis	66
1.10	Hypotheses	67
1.11	Aims	67
CHAPTER 2.	MURINE IMMUNOGENICITY STUDIES: OUTBRED MICE	71
2.1.	Introduction	71
2.2	Methods	72
2.2.1	Mouse strain, age and sex	72
2.2.2	Mouse housing	72
2.2.3	Vaccines	72
2.2.4	Vaccine transport	73
2.2.5	Temperature loggers	73
2.2.6	Vaccine storage	74
2.2.7	Anaesthesia	75

2.2.8	Blood collection	75
2.2.9	Immunisation	76
2.2.10	Mouse numbers	76
2.2.11	Measurement of pertussis IgG antibody responses	77
2.2.11.1	Reference Sera	79
2.2.11.2	Determination of antibody concentrations	79
2.2.12	Statistical analysis	80
2.3	Results	81
2.3.1	Vaccine storage	81
2.3.2	IgG antibody concentrations	81
2.3.2.1	Pre immunisation responses (day 0)	81
2.3.2.2	Post- immunisation antibody responses (day 28)	82
2.3.2.2.1	Mice immunised with normal saline	82
2.3.2.2.1.1	Investigation of high levels of background activity in EIAs	82
2.3.2.2.2	Mice immunised with DTPa or DTPw	83
2.3.2.2.3	Comparisons between all storage conditions	83
2.3.2.2.4	Comparisons between ideal storage and individual adverse storage conditions	84
2.3.2.2.4.1	Comparisons between storage at 2 ⁰ C to 8 ⁰ C and -3 ⁰ C for 24 hours	84
2.3.2.2.4.2	Comparisons between storage at 2 ⁰ C to 8 ⁰ C and -3 ⁰ C for 14 days	84
2.3.2.2.4.3	Comparisons between storage at 2 ⁰ C to 8 ⁰ C and -6 ⁰ C for 14 days	85
2.4	Conclusions	86
CHAPTER 3. IMMUNOGENICITY STUDIES: INBRED MICE		99
3.1	Introduction	99
3.2	Methods	99
3.2.1	Mouse strain, age and sex	99
3.2.2	Vaccine transport and storage	99
3.2.3	Mouse numbers	100
3.2.4	Mouse housing	100
3.2.5	Anaesthesia, blood collection and immunisation	100
3.2.6	Measurement of IgG antibody responses to pertussis antigens	101
3.2.7	Statistical analysis	101
3.3	Results	102
3.3.1	Vaccine storage	102
3.3.2	Pertussis IgG antibody responses	102
3.3.2.2	Pre-immunisation antibody responses (day 0)	102
3.3.2.3	Post immunisation antibody responses (day 28)	102
3.3.2.3.1	Mice immunised with normal saline	102
3.3.2.3.2	Mice immunised with DTPa or DTPw	103
3.3.2.3.3	Comparisons between inbred and outbred mice	103
3.4	Conclusions	106

CHAPTER 4. THE PROTECTIVE EFFICACY OF ADVERSELY STORED PERTUSSIS VACCINES: DEVELOPMENT OF THE MOUSE MODEL	114
4.1 Introduction	114
4.2 Review of methods of previous investigators	115
4.3 Development of the mouse model	116
4.3.1 Pilot study #1: general methodology	116
4.3.1.1 Mouse strain and age, method of challenge	116
4.3.1.2 Blood collection and immunisation	117
4.3.1.3 Preparation of challenge inoculum and intranasal administration	117
4.3.1.4 Sacrifice, lung homogenisation and bronchoalveolar lavage	119
4.3.1.5 Results	121
4.3.1.5.1 Culture results	121
4.3.1.5.2 Calculation of CFU/ml of <i>B. pertussis</i> in inoculum and lung homogenates	122
4.3.1.5.3 Lung weights	122
4.3.1.6 Summary of first pilot study	122
4.3.1.7 Alterations to the experimental methods	123
4.3.1.7.1 Anaesthesia	123
4.3.1.7.2 Contamination of lung homogenate cultures	123
4.3.1.7.3 Counting colony forming units	123
4.3.2 Pilot study #2: Investigation of the natural course of infection in unimmunised mice using two inocula of <i>B. pertussis</i> of different concentrations	123
4.3.2.1 Intranasal inoculum preparation and intranasal challenge	124
4.3.2.2 Sacrifice post challenge	124
4.3.2.3 Results	125
4.3.2.3.1 Inocula concentrations	125
4.3.2.3.2 Lung homogenates	125
4.3.2.3.3 Lung weights	126
4.3.2.3.4 Histopathological analysis of lungs	127
4.3.2.3.5 Summary of second pilot study	127
4.3.2.3.6 Alterations to methods after second pilot study	128
4.3.2.3.6.1 Mouse housing arrangements	128
4.3.2.3.6.2 Preparation of the inoculum	128
4.3.2.3.6.3 Preparation and dissection of mice after sacrifice	128
4.3.2.3.6.4 Agar plates used for culture of inocula and lung homogenates	128
4.3.2.3.6.5 Lung homogenisation and cleaning of homogeniser	128
4.3.3 Pilot study #3: assessment of outcome of modifications of experimental protocols from pilot study #2.	129
4.3.3.1 Results	130
4.3.3.1.1 Cultures of lung homogenates	130
4.3.3.1.2 Inoculum culture results	131
4.3.3.1.2.1 Bronchoalveolar lavage culture results	131
4.3.3.2 Summary	131
4.3.3.3 Modifications of experimental protocols after pilot #3	132
4.3.4 Pilot study #4: Investigation of natural course of infection at days 2 and 4 post intranasal challenge in unimmunised mice using two inocula of different concentrations and protocol modifications from pilot studies two and three.	132
4.3.4.1 Results	133
4.3.4.1.1 Inocula concentrations	133
4.3.4.1.2 Comparison of lung homogenate and BAL colony counts	133

4.3.4.2	Changes to experimental protocol after pilot study #4	133
4.3.5	Final protocol for the definitive protective efficacy experiments	134
4.3.5.1	Mouse strain and age	134
4.3.5.2	Housing of mice	134
4.3.5.3	Mouse handling	134
4.3.5.4	Day 0 and day 28 Immunisation and blood collection	135
4.3.5.5	Vaccine transport and storage	135
4.3.5.6	Preparation and quantification of challenge inoculum	135
4.3.5.7	Intranasal inoculation	136
4.3.5.9	Lung homogenisation	137
4.4	Conclusions	138
 CHAPTER 5. DEFINITIVE PROTECTIVE EFFICACY EXPERIMENTS: LUNG CLEARANCE STUDIES		146
5.1	Introduction	146
5.2	Additional methods	146
5.2.1	Vaccine storage prior to commencement of experiments	146
5.2.2	Vaccine storage conditions	146
5.2.3	Mouse numbers and time points for sacrifice post challenge	147
5.2.3.1	Assessment of efficacy at days 2, 4, 7 and 14 after challenge	147
5.2.3.3	Assessment of efficacy at day 4 after challenge	147
5.2.3.4	Statistical analysis	148
5.3	Results	149
5.3.1	Lung clearance in mice immunised with correctly stored vaccines	149
5.3.2	Comparisons between ideal storage and adverse storage of vaccines below 0°C	150
5.3.2.1	Inoculum concentrations	150
5.3.2.2	Day 0 lung homogenate culture results	150
5.3.2.3	Mice immunised with DTPa	151
5.3.2.4	Mice immunised with DTPw	151
5.3.2.5	Mice immunised with normal saline	152
5.3.2.6	Comparison between the protective efficacy of DTPa and DTPw in all experiments	152
5.3.4	Comparisons between ideal storage and storage of vaccines at +13°C for 48 hours prior to immunisation	152
5.3.4.1	Inoculum doses	153
5.3.4.2	Lung homogenate culture results	153
5.4	Conclusions	154
 CHAPTER 6. DEFINITIVE PROTECTIVE EFFICACY EXPERIMENTS: IGG ANTIBODY RESPONSES		162
6.1	Introduction	162
6.2	Methods of seroanalysis	162
6.2.1	Measurement of IgG antibodies to PT, FHA and PRN	162
6.2.1.1	Reference sera	163
6.2.2	Measurement of IgG antibodies to diphtheria and tetanus toxoids	163

6.2.3	Statistical analysis	165
6.3	Results	166
6.3.1	IgG antibody responses in mice immunised with correctly stored vaccines	166
6.3.1.1	Responses to pertussis antigens	166
6.3.1.1.1	Mice immunised with DTPa	166
6.3.1.1.2	Mice immunised with DTPw	166
6.3.1.1.3	Mice immunised with normal saline	167
6.3.1.1.4	Comparison between IgG antibody responses to DTPa and DTPw	167
6.3.1.2	IgG antibody responses to diphtheria and tetanus toxoids	167
6.3.1.2.1	Mice immunised with DTPa	167
6.3.1.2.2	Mice immunised with DTPw	168
6.3.1.2.3	Mice immunised with normal saline	168
6.3.1.2.4	Comparison between IgG antibody responses to DTPa and DTPw	168
6.3.2	Comparison of antibody responses between mice immunised with correctly stored vaccines and those immunised with vaccines stored below 0°C	168
6.3.2.1	IgG antibody responses to pertussis antigens	169
6.3.2.1.1	IgG responses in mice immunised with DTPa	169
6.3.2.1.2	IgG responses in mice immunised with DTPw	170
6.3.2.1.2.1	Comparisons between ideal storage and individual adverse storage conditions for DTPw in response to PT	170
6.3.2.1.2.2	Comparisons between ideal storage and individual adverse storage conditions for DTPw in response to FHA	170
6.3.2.1.2.3	Comparisons between ideal storage and individual adverse storage conditions for DTPw in response to PRN	170
6.3.2.2	IgG antibody responses to diphtheria and tetanus toxoids	171
6.3.2.2.1	Mice immunised with DTPa	171
6.3.2.2.2	Mice immunised with DTPw	171
6.3.3	Comparison between vaccine stored under ideal conditions and at +13°C for 48 hours	172
6.3.3.1	IgG antibody responses to pertussis antigens	173
6.3.3.1.1	Mice immunised with DTPa	173
6.3.3.1.2	Mice immunised with DTPw	173
6.3.3.1.3	Comparison between responses to DTPa and DTPw after immunisation with vaccine stored at +13°C for 48 hours	173
6.3.3.1.4	IgG antibody responses to diphtheria and tetanus toxoids	174
6.3.3.1.4.1	Mice immunised with DTPa and DTPw	174
6.3.3.1.4.2	Comparison between responses to DTPa and DTPw after immunisation with vaccine stored at +13°C	174
6.3.3.2	IgG antibody responses of mice immunised with normal saline	174
6.3.3.3	Correlation between lung clearance and pertussis IgG antibody concentrations four days after intranasal challenge	175
6.4	CONCLUSIONS	177

CHAPTER 7. DEFINITIVE PROTECTIVE EFFICACY EXPERIMENTS:

LUNG HISTOPATHOLOGY AND BRONCHOALVEOLAR LAVAGE FLUID ANALYSIS	199
7.1 Introduction	199
7.2 Methods	199
7.2.1 Preparation of lungs for histopathological analysis	199
7.2.1.1 Histopathological assessment of lung inflammation	200
7.2.2 Analysis of bronchoalveolar lavage fluid	200
7.2.2.1 Collection and storage of BAL fluid	200
7.2.2.2 Enzyme immunoassay cytokine analysis	201
7.2.2.2.1 Murine IL-2 and IL-4 EIA methods	201
7.2.3 Cytospin preparation and analysis	202
7.2.3.1 Cytospin slide preparation	202
7.2.3.2 Staining of cytospin slide preparations	202
7.2.3.3 Analysis of cytospin cellular composition	202
7.3 Results	203
7.3.1 Histopathological staging of mouse lungs	203
7.3.1.1 Comparisons between vaccine storage conditions	203
7.3.1.1.1 Comparison between vaccine treatment groups	204
7.3.1.1.1.2 Comparison between vaccine storage conditions	204
7.3.1.2 Histopathology score sub-components	204
7.3.1.2.1 Comparison between vaccine treatment groups	204
7.3.1.2.1.2 Comparison between vaccine storage conditions	205
7.3.1.2.1.2.1 Mice immunised with DTPa	205
7.3.1.2.1.2.2 Mice immunised with DTPw	205
7.3.1.2.1.2.3 Mice immunised with normal saline	206
7.3.2 BAL cytospin counts	206
7.3.2.1 Comparison by vaccine treatment group	206
7.3.2.2 Comparison by vaccine storage condition	207
7.3.2.2.1 Mice immunised with DTPa	207
7.3.2.2.2 Mice immunised with DTPw	207
7.3.2.2.3 Mice immunised with normal saline	207
7.3.3 BAL cytokine measurements	208
7.3.4 Correlations between lung histopathology mean scores and serology day 4 post challenge	208
7.3.5 Correlations between lung histopathology mean scores and mean lung homogenate culture results day 4 post challenge	209
7.4 Conclusions	210

CHAPTER 8. ANTIBODY RESPONSES TO ROUTINE IMMUNISATIONS IN PREMATURE AND TERM INFANTS 229

8.1	Introduction	229
8.2	Methods	231
8.2.1	Recruitment	231
8.2.1.1	Term infants, first study	231
8.2.1.2	Premature infants	231
8.2.1.2.1	First study	231
8.2.1.2.2	Second study	232
8.2.2	Recruitment criteria	232
8.2.3	Informed consent	233
8.2.4	Appointment schedule and data collection	233
8.2.5	Data management	234
8.2.6	Blood sampling procedures	234
8.2.7	Separation of serum, labelling and storage of samples	235
8.2.8	Immunisation procedures and vaccine details	235
8.2.8.1	Australian Immunisation Schedule	235
8.2.8.2.1	Management of infants unresponsive to the Hib vaccine after the primary course	236
8.2.8.2.2	Management of adverse events following immunisation	236
8.2.9	Sample size and power calculations	237
8.2.10	Materials and Methods of seroanalysis	237
8.2.10.1	Pertussis assays	237
8.2.10.1.1	Reference sera	239
8.2.10.1.2	Quality Controls (QCs)	239
8.2.10.1.3	Standardisation of the immunoassays	240
8.2.10.2	Anti-Diphtheria and anti-Tetanus toxoid IgG EIAs	241
8.2.10.3	Anti-PRP IgG antibody EIA	242
8.2.11	Statistical analysis	245
8.3	Results	246
8.3.1	First study	246
8.3.1.1	Numbers of infants recruited	246
8.3.1.2	Numbers of infants completing the study	246
8.3.1.3	Compliance with immunisation schedule	247
8.3.1.3.1	Premature infants	247
8.3.1.3.2	Term infants	247
8.3.1.4	Numbers of blood samples collected	248
8.3.1.5	Summary of demographic data	248
8.3.1.5.1	Sex distribution and birth weight	248
8.3.1.5.2	Ante- and postnatal corticosteroid medication	249
8.3.1.5.3	Duration of breast-feeding	249
8.3.1.5.4	Blood transfusions prior to immunisation	249
8.3.1.5.5	Time in hospital, in the Neonatal Intensive Care Unit (NICU) and Special Care Baby Unit (SCBU)	250
8.3.1.5.6	Duration of oxygen therapy	250
8.3.1.5.7	Health insurance	251
8.3.1.5.8	Adverse events following immunisation	251
8.3.2	Results of IgG antibody determination	252
8.3.2.1	Pertussis serology	252
8.3.2.1.1	Comparison of term and premature infant antibody concentrations	252

8.3.2.1.2	Comparison between term and premature infant subgroups	253
8.3.2.1.2.1	Comparison between term and extremely premature infants (gestation = 27 weeks)	253
8.3.2.1.2.2	Comparison between term and very premature infants (gestation 28-32 weeks)	253
8.3.2.1.2.3	Comparison between term and premature infants (gestation 33-36 weeks)	254
8.3.2.1.3	Comparisons between premature infant subgroups	254
8.3.2.1.4	Summary of pertussis serology results	254
8.3.2.2	Diphtheria and Tetanus serology	255
8.3.2.2.1	Comparison between term and premature infant responses	255
8.3.2.2.2	Comparison between term and premature infant subgroup responses	256
8.3.2.2.2.1	Comparison between term and extremely premature infants	256
8.3.2.2.2.2	Comparison between term and very premature infants	256
8.3.2.2.2.3	Comparison between term and premature infants (33-36 weeks gestation)	256
8.3.2.2.3	Comparison between premature infant subgroups	256
8.3.2.2.4	Proportion of infants in each age group achieving protective antibody concentrations	257
8.3.2.2.4.1	Diphtheria antibodies	257
8.3.2.2.4.2	Tetanus antibodies	257
8.3.2.2.5	Summary of diphtheria and tetanus serology results	258
8.3.2.3	Hib-PRP serology	258
8.3.2.3.1	Comparison between term and premature infant responses	258
8.3.2.3.2	Comparison between term and premature infant subgroup responses	259
8.3.2.3.2.1	Comparison between term and extremely premature infants	259
8.3.2.3.2.2	Comparison between term and very premature infants	259
8.3.2.3.2.3	Comparison between term and premature infants	259
8.3.2.3.3	Comparison between premature infant subgroups	259
8.3.2.3.4	Proportion of infants in each age group achieving protective antibody concentrations	260
8.3.2.3.4.1	Short-term protection	260
8.3.2.3.4.2	Long-term protection (determined at 7 and 19 months)	261
8.3.2.3.5	Summary of PRP serology results	261
8.3.2.4	Multiple regression analysis	262
8.3.2	Second study	263
8.3.2.1	Numbers of infants recruited in Cohort 2 and demographic characteristics	264
8.3.2.2	Longitudinal comparisons of IgG antibody responses between premature infants immunised with DTPa (cohort 1a) or DTPw in the primary series and DTPa at 18 months (cohort C)	265
8.3.2.2.1	IgG antibody responses to pertussis antigens	265
8.3.2.2.2	IgG antibody responses to diphtheria and tetanus toxoids	265
8.3.2.3	Longitudinal comparisons of IgG antibody responses between term infants immunised with DTPa (cohort 1b) or DTPw in the primary series and DTPa at 18 months (cohort D)	266
8.3.2.3.1	IgG antibody responses to pertussis antigens	266
8.3.2.3.2	IgG antibody responses to diphtheria and tetanus toxoids	266
8.3.2.4	Cross-sectional studies	267
8.3.2.4.1	Cross-sectional comparisons of IgG antibody 18 month booster responses between premature infants immunised with DTPa (cohort 2) or DTPw in the primary series and DTPa at 18 months (cohort C)	267

8.3.2.4.2	Proportion of infants with protective antibody concentrations of diphtheria and tetanus antibodies in cohorts 2, C and D.	268
8.3.2.4.3	Cross-sectional comparisons of IgG antibody responses between all newly recruited premature infants (cohorts 1a and 2 combined) and term infants (cohort 1b) at 18 and 19 months of age	268
8.3.2.4.3.1	IgG antibody responses to pertussis antigens	268
8.3.2.4.3.1.1	Comparisons between term and premature infants	268
8.3.2.4.3.1.2	Comparisons between term infants and premature infant subgroups	269
8.3.2.4.3.1.3	Comparisons between premature infant subgroups	269
8.3.2.4.3.1.4	Comparison of pertussis antibody results with first study	269
8.3.2.4.3.2	IgG antibody responses to diphtheria and tetanus toxoids	270
8.3.2.4.3.2.1	Comparisons between term and premature infants	270
8.3.2.4.3.2.2	Comparisons between term infants and premature infant subgroups	270
8.3.2.4.3.2.3	Comparisons between premature infant subgroups	271
8.3.2.4.3.2.4	Comparison of diphtheria and tetanus antibody results with first study	271
8.3.2.4.3.3	IgG antibody responses to Hib PRP	271
8.3.2.4.3.3.1	Comparisons between term and premature infants	271
8.3.2.4.3.3.2	Comparisons between term infants and premature infant subgroups	272
8.3.2.4.3.3.3	Comparisons between premature infant subgroups	272
8.3.2.4.3.3.4	Comparison of PRP antibody results with first study	272
8.4	Conclusions	273
8.4.1	First study	273
8.4.1.1	General trends in antibody concentrations	273
8.4.1.2	Pertussis antibodies	273
8.4.1.3	Diphtheria and tetanus antibodies	274
8.4.1.5	Hib PRP antibodies	274
8.4.2	Second study	280
8.4.2.1	Comparison of immunisation responses in infants immunised with DTP _w or DTP _a in the primary series and DTP _a at 18 months	280
8.4.2.1.2	Longitudinal comparisons	280
8.4.2.2.1	Cross sectional comparisons	280
8.4.2.2.1.1	Cross-sectional comparison of antibody responses in term and premature infants at 18 and 19 months using a combined cohort of premature infants	282
CHAPTER 9	DISCUSSION	317
9.1.	Murine Immunogenicity Studies	317
9.2	Murine Protective efficacy studies	319
9.3	Human immunogenicity studies	323
REFERENCES		327

Abstract

This thesis has examined the effect of adverse storage on the immunogenicity of pertussis, diphtheria and tetanus vaccines, the protective efficacy of pertussis vaccines and the effect of premature birth on antibody responses to routine childhood immunisations.

Methods

Murine Immunogenicity studies

Female Swiss outbred and Balb/c mice eight weeks of age were immunised intraperitoneally with whole cell pertussis vaccine (DTPw), acellular pertussis vaccine (DTPa) or normal saline on day 0 of each experiment. Blood was collected to determine IgG antibody responses to pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (PRN) on days 0 and 28. Vaccines were stored under ideal conditions (2⁰C to 8⁰C) or at -3⁰C for 24 hours prior to immunisation for both strains of mice and also at -3⁰C for 14 days or at -6⁰C for 14 days for Swiss outbred mice.

Murine Protective efficacy studies

The murine model was extended to include a second immunisation at 28 days, and an intranasal challenge of live pertussis organisms two weeks after the second immunisation, using Balb/c mice. Vaccines were stored under the same conditions as for the immunogenicity studies, and also at -6⁰C for 24 hours. At serial time points after challenge mice were sacrificed to determine lung clearance of organisms and IgG antibody responses to PT, FHA, PRN and diphtheria and tetanus toxoids. Bronchoalveolar lavages (BAL) for cell count and cytokine measurement and preparation of lungs for histopathological analysis were also performed in subsets of mice.

Human studies

Two studies were undertaken. In the first study, term and premature infants were recruited from two months of age to participate in a longitudinal study to determine IgG antibody responses to DTPa and Hib vaccine antigens before and after primary and 18 month booster immunisations. Comparisons were made between both term and premature infants and term infants and premature infant subgroups determined on the basis of gestational age at birth (extremely premature infants: gestational age at birth = 27 weeks, very premature infants: 28-32 weeks, premature infants 33-36 weeks).

In the second study, stored sera from premature and term infants enrolled in a previous study were used to perform longitudinal comparisons of the effect of immunising with DTPa or DTPw in the primary series and DTPa at 18 months on antibody responses to bacterial vaccine antigens. Cross sectional analyses were performed to confirm 18 and 19 month antibody concentrations in premature infants with different primary DTP immunisation schedules using the stored sera and sera from a second cohort of premature infants newly recruited at 18 months. In addition, further cross-sectional analyses were performed, by combining the two newly recruited premature infant cohorts and comparing term and premature infant and term and premature infant subgroup antibody responses to vaccine antigens at 18 and 19 months.

Results

Murine immunogenicity studies

In Swiss outbred mice, storage at -3°C for 24 hours significantly reduced vaccine immunogenicity in all cases except to PRN in DTPa. Other adverse vaccine storage conditions either had no effect on, or paradoxically produced higher antibody concentrations than ideally stored vaccines. Antibody responses to DTPa and DTPw in

Swiss outbred mice were higher than those in Balb/c mice. In both mouse strains, antibody responses to DTPa were greater, but more variable, than those to DTPw.

Murine protective efficacy studies

In general, adverse vaccine storage did not alter lung clearance rates of *B. pertussis* or murine IgG antibody responses to vaccine antigens in DTPa or DTPw or serological responses to immunisation. However, mice immunised with DTPw did not develop antibody responses to PT and demonstrated greater concentrations of diphtheria and tetanus antibodies and lesser concentrations of pertussis antibodies than mice immunised with DTPa. Mice immunised with normal saline did not demonstrate pertussis responses until 14 days after infection and these were of a very small magnitude. No significant correlations between serological responses and lung clearance were demonstrated in these mice when analyses were performed by vaccine and storage condition. However, some of the comparisons tended towards significance with moderately negative correlations demonstrated. Hence, larger numbers of mice may be necessary to achieve adequate power for these comparisons.

Immunisation with DTPa resulted in slightly more rapid lung bacterial clearance, less inflammation in stained lung sections, and fewer inflammatory cells in BAL fluid than mice immunised with DTPw or saline. Mice immunised with DTPa and normal saline demonstrated a Th-2 type cytokine response in BAL fluid, whereas immunisation with DTPw conferred a Th-1 cytokine profile. None of these parameters was affected by adverse vaccine storage.

Human studies

The general pattern of IgG antibody concentrations at different study time was consistent in both term and premature infants, with low level of maternal antibodies detected at 2 months, increased responses after primary immunisation measured at the 7 month study time, a decline in antibody concentrations at the 18 month study time with increased booster responses measured at the 19 month study time.

Premature infants demonstrated lower concentrations of IgG antibodies to all vaccine antigens throughout the cohort survey period. These were significantly lower than term infants in response to pertussis vaccine antigens at all study times with one exception (PRN at 19 months). In contrast, premature infant responses to diphtheria and tetanus toxoids and Hib PRP were not, in general, significantly lower than those of term infants. Extremely premature infants demonstrated the lowest antibody concentrations, and the magnitude of antibody responses in premature infants increased with increasing gestational age at birth.

Premature immunised with DTPa from two months of age in general demonstrated significantly higher antibody responses to pertussis antigens after primary and 18 month booster immunisations, but significantly lower responses to diphtheria and tetanus toxoids than premature infants immunised with DTPw in the primary series and with DTPa at 18 months regardless of gestational age at birth. Term infant comparisons were similar, at 7 months, but there were no statistical differences in PT, FHA or diphtheria antibody concentrations between the two groups of term infants at 19 months.

Combining the two newly recruited premature infant cohorts confirmed the term and premature infant comparisons of the first study with regard to PT, FHA, PRN and Hib PRP

antibody concentrations at 18 and 19 months. However, comparisons between term infants and premature infant subgroups were altered: very premature infant pertussis antibody concentrations became more comparable with those of term infants. Extremely premature infant pertussis antibody concentrations remained significantly lower than those of term infants. Diphtheria and tetanus antibody concentrations at 18 and 19 months were affected unpredictably by the addition of a second cohort of premature infants in the analyses.

Conclusions

Although adverse storage does not appear to diminish vaccine immunogenicity or protective efficacy in the short term, vaccines should be stored according to the manufacturers instructions until long term efficacy studies can be performed.

Premature infants demonstrated lower IgG antibody concentrations to all vaccine antigens, but were able to mount protective antibody responses to diphtheria and tetanus toxoids and Hib PRP. Premature infant responses to pertussis vaccine antigens were, in general, significantly lower than those of term infants at all study times, despite evidence of increased antibody concentrations after primary and 18 month booster immunisations. Extremely premature infants demonstrated the lowest antibody concentrations to all vaccine antigens, and in particular to pertussis vaccine antigens. There is no single serological correlate of protection against pertussis infection, however, and antibody avidity and cell-mediated immune responses were not examined in these infants. Therefore these parameters should be explored before changes are made to the immunisation schedule of premature infants.